Smith+Nephew first to market with revision knee indication on robotics platform
Retrieved on:
Monday, September 26, 2022
United States Patent and Trademark Office, Legislation, Health, Phrase, Patient, U.S. Securities and Exchange Commission, Duke University, Technology, CT, ENT, TKA, CORI, NJR, Annual report, 3D, Longevity, FTSE100, Knee, HQIP, Unlimited, International Society, Robotics, Group, Surgeon, Smith & Nephew, Patent, Northgate Public Services, View, Failure, NPS, NYSE, FDA, Healthcare Quality Improvement Partnership, Regeneration, Forward-looking statement, United States patent law, LSE, Instagram, Poster, Hospital, Form 20-F, SNN, Sports medicine, Digital, Gaps, Twitter, LinkedIn, Learning curve, Data analysis, General manager, LEGION, Multimedia, Medical device, Medical imaging, Computer data storage, COVID-19, Limited, Facebook
Smith+Nephew is the first orthopaedics company to receive FDA 510(k) clearance for a revision indication using a robotics-assisted platform.
Key Points:
- Smith+Nephew is the first orthopaedics company to receive FDA 510(k) clearance for a revision indication using a robotics-assisted platform.
- Surgeons can now experience the power and versatility of one robotics platform when using the CORI Surgical System.
- With broader capabilities and expanded indications, it can address robotic-assisted total, partial, and now revision knee arthroplasty, along with computer-guided total hip arthroplasty.
- "Beingfirst to market with a revision indicationfor robotic-assisted knee replacement surgeryis a significant milestone in orthopaedics," said Randy Kilburn,Executive Vice President & General Manager, Orthopaedic Reconstruction, Robotics and Digital for Smith+Nephew.